NCT06026488 Real-World Study of DLBCL With Different Genetic Subtypes
| NCT ID | NCT06026488 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | DLBCL - Diffuse Large B Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2023-10-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Eligibility Criteria
Inclusion Criteria: * Histologically-confirmed diffuse large B-cell lymphoma (DLBCL) * Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others * Fully comprehension and signature of the informed consent form (ICF) for participation Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period * Severe mental illness * Patients deemed unsuitable for inclusion by the investigator
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06026488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying DLBCL - Diffuse Large B Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06026488 currently recruiting?
Yes, NCT06026488 is actively recruiting participants. Contact the research team at zwl_trial@163.com for enrollment information.
Where is the NCT06026488 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06026488 clinical trial?
NCT06026488 is sponsored by Ruijin Hospital. The trial plans to enroll 10,000 participants.